Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Atlab Pharma has entered into a sublicense agreement with BZL Biologics for developing 177Lu-J591, a radiopharmaceutical product used to treat cancer.
Subscribe to our email newsletter
The agreement comprises exclusive rights to manufacture, develop and commercialize the drug candidate across the globe, besides a joint Phase IIB/III clinical validation program.
In addition, Atlab Pharma will also fund certain product development and clinical trials.
Lu-J591, a tumor-specific delivery system comprises humanized J591 monoclonal antibody targeting prostate-specific membrane antigen (PSMA) in addition to the 177Lu radioisotope.
Phase I and Phase II trials comprising 108 patients with metastatic castrate-resistant prostate cancer, demonstrated efficacy and tolerability of 177Lu -J591.